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Abstract 
Atorvastatin calcium, a lipid-lowering drug, is much less bioavailable because of 
reduced solubility in acidic media. Multiple-unit floating microcapsules of 
Atorvastatin calcium (ATC) were developed to expand the gastric residence 
time of the drug, as ATC has maximum rate of absorption in the upper GI tract. 
Floating microcapsules were prepared by Emulsion-solvent evaporation 
technique through incorporation of dioctyl sodium sulphosuccinate (DSS) as a 
dissolution enhancer. The microcapsules were assessed for shape, size, drug 
entrapment efficiency, stability and  in-vitro  drug dissolution rate and were 
subjected to SEM, DSC and PXRD studies. The ATC-loaded floating 
microcapsules were spherical in shape and had the particle size of about 28.10 
µm and drug-loading efficiency of about 96.55 %. The floating microspheres 
containing DSS had significantly higher drug dissolution rates than those 
without DSS. The best formulation, AT4, consisting of Ethyl cellulose, DSS and 
Poly Ox®, had a maximum drug dissolution rate of 97.86 %, as compared to 
Storvas 80 mg (Ranbaxy Ltd, as a reference) which had a rate of only 54% 
during a period of 12 h in acidic media. A pharmacokinetic study performed on 
albino rabbits illustrates that the bioavailability of AT4 floating microcapsules 
significantly increased to nearly 1.7 times that of Storvas 80 mg. The present 
study indicates that the use of multi-unit floating microcapsules for delivery of 
ATC can improve its bioavailability. 
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Introduction  
Atorvastatin calcium (ATC) is the treatment of choice in moderate to severe familial or non-
familial hypercholesterolemia. ATC has a maximum rate of absorption in the upper GI 
tract, but because of poor solubility in this region, it is less bioavailable. Unpredictable and 
short gastric emptying time can result in incomplete drug release from the drug delivery 
system above the absorption region, which may be the stomach or upper component of 
the small intestine, leading to a reduced systemic availability of the administered dose. A 
previous study investigating improved solubility, stability and bioavailability of ATC includes 
a tablet formulation containing a complexing agent (cyclodextrins) and a surfactant (d-alpha 
tocopherol polyethylene glycol 1000 succinate) [1]. A self-micro emulsifying drug delivery 
system (SMEDDS) of ATC consisting of Labrafil, propylene glycol and Cremophor RH40 
has been developed [2]. Recently, another self-emulsifying drug delivery system (SEDDS) 
of ATC in various vehicles such as Captex 355, Captex 355 EP/NF, Ethyl oleate, Capmul 
MCM, Capmul PG-8, Gelucire 44/14, Tween 80, Tween 20, and PEG 400 has been 
reported [3]. All these drug delivery systems have the disadvantage of complex 
manufacturing procedure and use of expensive additives with additional equipment and 
apparatus. The negative aspect of formerly reported solo unit systems such as tablets and 
capsules are the high inconsistency of their GI transfer moment because of their all-or-
nothing emptying course of action. To overcome these limitations, multiple-unit floating 
microcapsules have been developed to form cost-effective stable ATC formulation with 
enhanced bioavailability. Multi-unit floating microcapsules  will  ensure  a complete and 
constant drug release, particularly for drugs absorbed in the specific gastric area [4]. Such 
a dosage form can be circulated extensively throughout the gastrointestinal tract (GIT), 
providing a longer and more dependable release of the drug from the dosage form. 
Therefore, the focus of this research was to develop solubilized gastro-retentive multi-unit 
floating microcapsules of ATC to achieve better bioavailability.  
Materials and methods 
ATC was obtained as a gift sample from Lupin India Ltd. Ethyl cellulose (Aqualon® N50), 
Hydroxy propyl methyl cellulose (Metolose® K4M) and Polyethylene Oxide (Poly Ox® 
N10) were provided as a gift sample by Colorcon Asia Pvt Ltd, Hydroxy propyl cellulose 
(Klucel G® 300) was supplied as a gift sample by Hercules Aqualon division. Light paraffin 
(LLP) and petroleum ether (40–60°) were purchased from Merck (India) and Dioctyl 
sodium sulphosuccinate (DSS granular) from Cytec Industries Inc.; all other chemicals 
were of analytical grade. 
Initial development of microcapsules 
Floating microcapsules of ATC were prepared by emulsion solvent evaporation technique 
using different polymers such as EC, HPMC, HPC and Poly Ox® (Drug: polymer: DSS, 
1:4:2) Table 1. Microcapsules with EC were prepared by dissolving ATC in 2ml methanol; 
EC and DSS were dissolved in acetone (8ml). The two solutions were mixed and dropped 
into a solution of light liquid paraffin 200 ml containing 0.25% Sorbitan monolaurate. The   Enhanced Bioavailability and Dissolution of Atorvastatin Calcium from Floating Microcapsules …  217 
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solution was stirred using a digitally controlled mechanical stirrer for 3 h at 800 RPM. After 
evaporation, microcapsules formed were collected by filtration and washed three times 
with petroleum ether and dried under vacuum at room temperature overnight. While the 
HPMC and HPC microcapsules are prepared by the same procedure as that of EC 
microcapsules, the only variation is the mixture of ethanol and dichloromethane (1:1) used 
for dissolving HPMC and HPC. All microcapsule formulations were prepared in triplicate. 
The prepared microcapsules were mixed with microcrystalline cellulose 10% and 
lubricated with 0.1% Magnesium stearate. Then, the final blend was compressed into 
tablets on 8 station rotary compression machine (Rimek, R&D model, “D” tooling), using 
suitable punches and dies. 
In-vitro floating ability 
Microcapsules approximately 500 mg were introduced in dissolution apparatus consisting 
of 900 mL of 0.1 N HCL with 0.02% tween 80. The RPM (revolution per minute) was set at 
100 and stirred for 12 h. The buoyant and the settled microcapsules were recovered, dried 
and weighed separately. The percent buoyant microcapsules were calculated as the ratio 
of quantity of microcapsules that were floating and the total quantity of the microcapsules 
[5]. 
Physical state determination 
The surface morphology of prepared microcapsules was determined by Jeol scanning 
microscope Japan (JSM 6015). Random SEM images of microcapsules were taken to find 
out shape, structural integrity and porosity.  
Determination of drug content and encapsulation Efficiency  
Microcapsules equivalent to 80 mg of ATC was crushed and extracted with methanol and 
after appropriate dilution with 0.1N HCl, it was subjected to drug content analysis UV-
visible spectrophotometer (V630, Jasco, Japan) at a wavelength of 246 nm. Drug 
concentration was determined with the help of the calibration curve. The range of drug 
concentration in the calibration curve was 5–100 μg/ml [6]. The entrapment efficiency was 
determined using the following formula:  




Differential Scanning Calorimetry 
Thermal characteristics of drug and drug excipients mixture were studied using a 
differential scanning calorimeter to ascertain that the drug is in pure form and there is no 
chemical interaction between the drug and the excipients during manufacture and storage. 
DSC measurements were performed on a Mettler-Toledo 821 instrument at a heating rate 
of 5°C/min, starting from 40 to 300°C. 
Assessment of Crystallinity  
In order to determine the physical state of the drug before and after microcapsule 
preparations, the XRD patterns of the pure drug and the formulations were investigated 
using an X-pert pro and Pro-Anac diffractometer, Netherlands. The samples were 
irradiated with monochromatized CuKα radiation, and the scanning range (2θ) was from  218  F. N. Khan and M. H. G. Dehghan:   
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2–50°. The voltage and current were set to 30kv and 30mA, respectively. X-ray patterns 
were analyzed using an X-pert data collector and X-pert data viewer V-1.0 software. 
In-vitro drug dissolution study 
In-vitro  drug dissolution rate determined by USP type II (USP XXIV) dissolution test 
apparatus. The study was conducted at 37 ± 0.5°C with agitation speed of 100 rpm in 
0.1 N HCL (900 ml) as a dissolution medium. The samples were collected and filtered at 
predetermined time points, replaced with fresh media. Drug content in the samples were 
estimated by Jasco (PU2080 pump) HPLC system, with reverse phase Hi Qsil, 250mm x 
0.45 ID, 5µm C18 column, and mobile phase comprising acetonitrile and phosphate buffer 
pH 3 in the 70:30 ratio, respectively. The wavelength was set at 246 nm at a flow rate of 
1ml per minute [5].  
Stability studies  
Stability studies were carried out according to International Conference on Harmonization 
(ICH) guidelines. The samples were stored at 40 ± 0.5°C/ 75 ± 5% RH (relative humidity) 
and 25 ± 0.5°C/ 60 ± 5% RH for three months. The samples were withdrawn and 
evaluated for drug content and physical change [7].
 
Pharmacokinetics of ATC floating microcapsules 
The protocol for the animal study in prescribed proforma B was approved by the IAEC 
approval no: CPCSEA/IAEC/P’ceutics-05/2010-11/27. Albino rabbits of both sexes 
weighing 2–3 kgs were fasted overnight and divided into two groups. Conventional tablets 
of 40mg x 2 (Storvas (40 mg, Mfd by: Ranbaxy Ltd) as reference was administered to 
group A. Because one 80 mg conventional tablet is too big to be administered to rabbits, 2 
tablets of 40 mg strengths were administered consecutively one by one to ease of 
administration, and AT4 tablets equal in strength to the 80 mg floating microcapsules were 
given to group B. Blood samples were collected at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 h. 
Blood samples (3ml) were withdrawn from the marginal ear vein. Whole blood withdrawn 
was centrifuged to separate serum. 1 ml was pipetted, deprotinated and diluted with 
acetonitrile to make 0.1μg/ml of drug solution. Estimation of ATC was performed by high-
performance liquid chromatography (HPLC) analysis  [6].  Extracted drug samples of 
plasma were assessed with a Jasco (PU2080 pump) HPLC system, with reverse phase Hi 
Qsil, 250mm x 0.45 ID, 5µm C18 column, and mobile phase comprising acetonitrile and 
phosphate buffer pH 3 in the 70:30 ratio, respectively. The wavelength was set at 246 nm 
at a flow rate of 1ml per minute. The calibration curve was plotted between the 
concentration ranges of 10 to 100 µg/ml that showed a correlation coefficient of 0.9992. 
The retention time of the ATC acid was 4.2 min. 
Results and discussion  
Initial development of microcapsules 
Microcapsules were prepared by solvent evaporation method. ATC have very low solubility 
characteristics of acidic media, and to facilitate drug release, a water-soluble polymer such 
as Poly Ox® or HPMC or HPC was used along with a water insoluble polymer such as EC. 
The effect of incorporation of polymers such as Poly Ox®, HPMC, HPC, and EC on 
microcapsules characteristics such as size, shape, entrapment efficiency, yield and drug   Enhanced Bioavailability and Dissolution of Atorvastatin Calcium from Floating Microcapsules …  219 
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content was determined. The different formulations prepared are listed in Table 1. 
Microcapsules prepared by the EC alone were consistent, spherical and regular, whereas 
with HPC and HPMC alone or in combination with EC had irregular shape and were 
inconsistent. The irregular shape of microspheres consisting of HPMC or HPC may be 
because of a reduction in external volume as a result of the drying process. Quick water 
loss and heating promotes strains in the cellular structure of the materials, leading to a 
change in shape by means of shrinkage and formation of a concave surface [8]. 
Incorporation of Poly Ox® at 50 mg concentration did not affect the overall microcapsule 
characteristics such as shape and consistency as compared to HPMC and HPC. Based on 
these observations, EC and Poly Ox® polymers were selected for further studies. 
Tab. 1.  Characteristics of the initial development of microcapsules. 
Batch 
Nr. 






M1  EC/ATC (4:1)  82  45 ± 12.45  93.22  97.59 
M2  HPMC/ATC (4:1)  57  150 ± 35.22  87.01  91.81 
M3  HPC/ATC (4:1)  60  171 ± 37.89  89.89  90.28 
M4  EC: HPMC/ATC (4:4:1)  65  120 ± 28.56  92.12  95.64 
M5  EC: HPC/ATC (4:4:1)  59  129 ± 31.65  91.38  95.12 
M6  HPMC: HPC/ATC (4:4:1)  50  252 ± 26.44  82.65  89.33 
M7  EC: Poly Ox® (4:0.5)  81  44 ± 39.45  94.04  96.98 
 
A 3
2 factorial design was used to design the batches of microcapsules for optimization 
studies. The two independent variables selected were amount of drug and amount of 
polymer, and their effect on drug dissolution rate was observed. All the floating 
microcapsule formulations were compressed into tablets and had good physical 
parameters such as hardness, friability, weight variation, disintegration etc. The prepared 
tablets were made to deliver microcapsules to the stomach, where the tablet disintegrates 
and releases the microcapsules in the stomach. As soon as these microcapsules are 
released in the stomach they float instantaneously in the acidic media. The physical 
parameters of formulations AT1to AT9 such as hardness and friability were satisfactory 
with % friability and disintegration time below 0.2% and 60 seconds, respectively, as 
shown in Table 3. 
In-vitro floating ability 
The buoyancy percentage of the microcapsules observed was in the range of   
74.33–91.16 ± 1.22% for formulation AT1 to AT9 at the end of 12 h. Tween 80 was 
incorporated in the medium for the wetting effect, to simulate the natural surface-active 
agents in the GIT. Microcapsules floated for an extended period of time on the surface of 
the medium without any noticeable gelation. The nature of the polymer influenced the 
floating behavior of the microcapsules. The results of % buoyancy for formulations AT1to 
AT9 are given in Table 2. The microcapsules containing higher polymer concentrations 
have high density and are less buoyant than those with lower polymer concentrations [9].  
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Tab. 2.  Factorial design batches with variables and their level. 
Batch  
Code 






AT1  −1  −1  76.02±2.11  26.80±7.27  93.94±2.57  90.67±1.55 
AT2  −1  0  71.72±2.32  28.51±5.30  95.67±3.61  85.00±1.26 
AT3  −1  +1  98.50±1.84  32.39±9.63  84.51±1.07  76.33±1.47 
AT4  0  −1  74.17±1.38  28.10±6.58  96.55±4.05  91.16±1.22 
AT5  0  0  71.25±2.35  30.03±8.43  71.05±3.84  87.34±1.42 
AT6  0  +1  95.64±1.89  36.29±5.39  86.99±2.01  78.67±1.39 
AT7  +1  −1  73.32±1.71  29.61±5.41  79.33±1.85  84.54±1.77 
AT8  +1  0  80.82±2.12  32.25±6.09  81.08±2.45  80.88±1.51 
AT9  +1  +1  93.00±2.19  41.43±4.11  87.95±2.11  79.15±1.96 
Amount of Drug X1 = +1 (150mg), 0 (100mg), −1 (50mg); Amount of Polymer X2 = +1 
(450mg), 0 (400mg), −1 (350mg); * Amount of DSS = 200 mg and Poly Ox® =50 mg were 
kept constant in all the batches; Drug content analyzed after 3 months of storage. 
 
Determination of drug content and encapsulation efficiency  
Drug content of all the microcapsule formulations was above 80% as reported in Table 1. 
The highest drug content of 97.59 % was observed in EC microcapsules (M1) because of 
good encapsulation efficiency. The M2 and M3 formulations containing HPMC:EC and 
HPMC:HPC, respectively, resulted in low drug content which might be because of low 
encapsulation efficiency, as the microcapsules formed by these polymers are irregular and 
distracted. When EC was used in combination with HPMC (M4) and HPC (M5), the drug 
content was increased, but it was less than EC (M1) alone. Good entrapment efficiency of 
93.22 % was recorded for M1. However, drug content of HPMC and HPC can be increa-
sed by varying HPMC:HPC ratio (1:4), but this resulted in a tacky and soft formulation.  
The quantity of EC used on drug encapsulation efficiency revealed that, as the polymer 
quantity increased, encapsulation efficiency decreased (Batch no: AT3, AT6 and AT9). 
The emulsion-solvent evaporation technique using EC (AT4) resulted in microcapsules 
with good encapsulation efficiency of 96.55%.  


















After 3 M (%) 
AT1  3.5±0.47  2.5±0.05  0.10±0.07  43.2±0.33  96.28±1.15  96.01±0.50 
AT2  3.4±0.83  2.6±0.08  0.15±0.05  31.2±0.42  98.51±0.53  98.26±0.83 
AT3  3.5±0.84  2.4±0.05  0.13±0.02  52.2±0.38  90.89±0.81  90.63±0.64 
AT4  3.5±0.50  2.5±0.04  0.11±0.05  35.2±0.29  98.97±0.54  98.86±0.87 
AT5  3.5±0.65  2.6±0.01  0.12±0.05  59.2±0.24  81.08±0.76  80.95±1.10 
AT6  3.4±0.43  2.6±0.02  0.17±0.04  45.2±0.41  89.43±1.22  89.22±1.05 
AT7  3.4±0.41  2.5±0.01  0.12±0.06  30.2±0.32  87.54±1.09  87.41±0.93 
AT8  3.6±0.87  2.4±0.06  0.14±0.03  40.2±0.29  89.88±0.85  89.71±0.81 
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Physical state determination 
The diameter of all the batches except EC microcapsules was above 100 μm. As the 
concentration of EC increased, the microcapsule yield decreased. The results were similar 
when HPC and HPMC microcapsule were prepared. The particle size of HPMC 
microcapsules was 150 ± 35.22 μm and 171 ± 35.22 μm for HPC was observed at a 
polymer: drug ratio of 4:1, as the polymer concentration was decreased, more distracted 
particles were observed for both the polymers. The morphology of the factorial batches 
shows that the size of the microcapsules was controlled by EC concentration. The particle 
size increased with increasing EC concentration (AT9). The particle size of EC 
microcapsules was between 26.80 to 45.43 μm, as shown in Table 2. An SEM image 
shows that microcapsules obtained were spherical and no surface drug absorption on 
loaded microcapsules was observed. This demonstrates that the drug is equally distributed 
within the polymer coat, Figure 1. The mean particle size of the microcapsules increased 
considerably with increased polymer concentration, which may be because of high 
viscosity of the system at a greater polymer concentration leading to enhanced interfacial 
tension and reduced shearing efficiency [4]. The SEM images of single blank EC 
microcapsules showed surface porosity, which could be attributed to rapid solvent 
evaporation during preparation. However, this was absent in AT4 formulation because of a 
change in boiling point of acetone by the presence of ATC. 
 
Fig. 1.  SEM of Blank EC Microcapsules (A, upper left); 
SEM of single Blank Microcapsule (B, upper middle); 
SEM of surface topography of blank EC Microcapsule (C, upper right); 
SEM of ATC loaded Microcapsules (D, bottom left); 
SEM of ATC loaded single Microcapsule (E, bottom middle); 
SEM of surface topography of ATC loaded Microcapsule (F, bottom right). 222  F. N. Khan and M. H. G. Dehghan:   
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Differential scanning calorimetry 
To determine the physical character of the drug before and after microcapsule formation, 
DSC analysis was performed for the pure drug, microcapsule formulation and placebo. 
Thermograms of the single component and final formulation are shown in Figure 2. DSC 
curve A of pure ATC showed an endotherm of water loss in the temperature range of  
90–120 °C and a sharp endotherm at 164°C suggested the melting point of ATC. Curve B 
is the AT4 microcapsule formulation, which shows the melting transition at 168°C indicates 
that the drug is still in the crystalline form and the absence of endotherm of water loss in 
the temperature range of 90–120 °C in microcapsule formulation may be because of the 
conversion of trihydrate form to anhydrous form [10]. Slight shifting of the peak may be 
caused by the presence of other excipients. Curve C is the thermogram of placebo. 
 
Fig. 2.  DSC thermogram of pure drug (A), AT4 microcapsules (B), Placebo without 
drug (C). 
Powder X-ray diffraction (pXRD) 
The diffraction pattern of pure drug showed characteristic high-intensity diffraction peaks at 
8.96, 9.35, 10.01, 10.37, 11.65, 12.00, 16.85, 19.26, 21.36, 22.50, 23.12, and 23.51, which 
indicates that the drug is present in the crystalline form that is also confirmed by DSC 
results, whereas AT4 microcapsule formulation showed reflections at 17.18, 18.66, 21.08, 
and 23.3. The pure drug exhibits reflections at 8.9, 9.3 and 10, these strong reflections of 
pure drug were masked in the microcapsule formulation and exhibits weak reflections at 
8.9, 9.3 and 10 (two theta) 2θ. This decrease in intensity of reflection is attributed to the 
presence of other excipients in the formulation [11], Figure 3. It is clear that the reflections 
of the pure drug match satisfactorily with the reflections of the drug in the microcapsule   Enhanced Bioavailability and Dissolution of Atorvastatin Calcium from Floating Microcapsules …  223 
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formulation. Thus, it can be concluded that the polymorph of pure drug was the same as 
that of ATC polymorph incorporated in microcapsules, and no transformation took place 
during the manufacturing process and storage. 
 
Fig. 3.  XRD diffractograms of pure drug (A), AT4 microcapsules (B), Placebo without 
drug (C). 
Drug dissolution studies 
The quantity of polymer affects the particle size as well as the dissolution of ATC from 
microcapsules. The polymer-drug ratio along with the amount of surfactant DSS may be 
the influential factor in the dissolution of ATC from the EC microcapsules. Different 224  F. N. Khan and M. H. G. Dehghan:   
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solubilizers such as DSS, Poly Oxyethylene Sorbitan Fatty Acid Esters (Tween 80), 
Sorbitan monolaurate (Span 20), polyethylene–propylene glycol copolymer (Polaxomer) 
etc.,  were used, and their effect on physicochemical properties of microcapsules was 
determined. Among all the solubilizers used, only  DSS was able to enhance the 
dissolution of ATC in 0.1 N HCL with 80% of dissolution in 8 h, as compared to the other 
polymer mixtures and pure drug as shown in Table 4. DSS also helps in maintaining the 
integrity of the microcapsules during the development process and dissolution study. DSS 
is widely used as an anionic surfactant in pharmaceutical formulations to assist in wetting 
and dissolution,  [12, 13].  Above 50 mg and 100 mg concentration of Poly Ox® and 
Poloxamer, the matrix of the microcapsules began to dissolve within 2-3 h of dissolution. 
Beyond certain concentrations of other polymers used in the dissolution study, it hampered 
the microcapsule formation in terms of shape and consistency. The drug dissolution 
percentage of Storvas 80 mg tablet was only 55% in 12 h of dissolution in acidic media as 
compared to the rate of ATC floating microspheres, which was 97.86%, 95.69% and 
89.31% for AT4, AT5, and AT7, respectively. The drug dissolution significantly decreased 
with an increase in the amount of polymer in the microcapsules, and the higher density of 
the polymer matrix because of more concentrations gives rise to an increased diffusional 
pathlength. This may lead to decrease in overall drug release from the polymer matrix. 
Moreover, smaller microspheres are formed at a lower polymer concentration and have a 
larger surface area exposed to dissolution medium, giving rise to quicker drug release, 
Figure 4. 
Tab. 4.  In-vitro drug dissolution studies  














8th hour (%) 
400:100  200  –  –  –  –  –  –  80 ± 0.64 
400:100  –  50  –  –  –  –  –    5 ± 0.57 
400:100  –  –  100  –  –  –  –    7 ± 0.31 
400:100  –  –  –  100  –  –  –  26 ± 0.43 
400:100  –  –  –  –  100  –  –  52 ± 0.48 
400:100  –  –  –  –  –  50  –  46 ± 0.52 
400:100  –  –  –  –  –  –  50  35 ± 0.59 
pure 
drug  –  –  –  –  –  –  –  10 ± 0.39 
n = 3; Mean ± SD. 
 
Stability studies 
Stability studies on optimized batch AT4 of EC microcapsules determined at 40 ± 0.5°C/ 
75 ± 5% RH and 25 ± 0.5°C/ 60 ± 5% RH for a period of 3 months showed no physical 
change and drug content determined corresponded to the earlier initial results obtained 
before storing of microcapsules, as shown in Table 3. The anionic surfactant DSS provides 
the necessary stability to the formulation by maintaining the sufficient alkaline conditions 
during storage and dissolution studies. Therefore, it may be suggested that no chemical 
interaction between excipients and ATC took place.    Enhanced Bioavailability and Dissolution of Atorvastatin Calcium from Floating Microcapsules …  225 
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Fig. 4.  Dissolution profile of factorial batches from AT1 to AT9 and reference tablet 
Storvas 80mg in 0.1 N HCl. 
Pharmacokinetics of ATC floating microcapsules 
The plasma concentration versus time profile of AT4 floating microcapsules and the 
conventional tablets is shown in Figure 5. Microcapsule formulation is well absorbed as 
there is a complete dissolution in acidic media owing to greater surface area for 
dissolution, without degradation of the drug when compared to conventional tablets, as 
Cmax of microcapsules is higher  than that of conventional tablets (665 ng/ml for 
microcapsules and 478 ng/ml for conventional tablets). The pharmacokinetic parameters 
such as AUC and Cmax show significant differences between the two formulations. There 
were no significant differences between the two formulations for t1/2 and tmax. The C max 
and AUC0→24h of the floating microcapsules were significantly higher than those of the 
conventional tablet. The relative bioavailability of AT4 formulation was about 1.7 fold 226  F. N. Khan and M. H. G. Dehghan:   
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compared with the conventional tablet, Table 5. This may be because of complete 
solubilization and better absorption of ATC. Therefore, ATC floating microcapsules can 
increase the oral bioavailability of ATC. 
Tab. 5.  In-vivo pharmacokinetic parameters of ATC and relative bioavailability of AT4 
microcapsules and conventional tablets. 
Formulation  Tmax (h)  Cmax (ng/ml)  AUC0–24h (ng.h/ml)  Fr (%) 
Conventional Tablet  2.00 ± 0.48  478 ± 24.22  2557.51 ± 319.57  100.00 
EC microcapsule (AT4)  1.98 ± 0.25  665 ± 33.16  4490.22 ± 431.88  175.60 
n = 6; Data are means ± SD. 
 
 
Fig. 5.  Plasma concentration time profiles of conventional tablet and AT4 microcapsule 
formulation. 
Conclusion 
The floating microcapsules of ATC-containing ethyl cellulose, Poly Ox®, docusate sodium, 
shows signs of good results with respect to incorporation efficiency, percentage yield, 
solubility and sustained drug dissolution rates. The AT4 formulation is capable of complete 
drug dissolution within 12 h. The developed floating microcapsules have the potential to 
enhance the oral bioavailability of ATC. After oral administration of ATC to rabbits, the 
bioavailability of ATC significantly increased by nearly 1.7 times compared with that of the 
conventional tablets. The present study shows that multi-unit floating microcapsules of 
AT4 are the best formulation for improved systemic availability of ATC. 
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